TopDollar Investing

[Slimer84]

Huifeng Bio-Pharmaceutical Technology Announces the Reinspection Approval of GMP Certificate

Sep. 23, 2010 (PR Newswire) --

XIAN, China, Sept. 23, /PRNewswire-Asia-FirstCall/ -- Huifeng Bio-Pharmaceutical Technology, Inc. (OTC Bulletin Board: HFGB) ("the Company"), specializing in developing and producing botanical extracts and other raw materials for pharmaceuticals and food additives, today announced the reinspection approval of Good Manufacturing Practice ("GMP") certificate by the State Food and Drug Administration (SFDA) on September 7, 2010. All pharmaceutical companies in China are required by SFDA to gain GMP Certificate for the production of pharmaceuticals.

The implementation of Good Manufacturing Practice ("GMP") is an effective measure for assuring the quality, safety, and effectiveness of pharmaceutical products. Such GMP certificate is valid for five years. After the validity period has transpired, a full inspection will be conducted by SFDA to check whether the drug manufacturer still meets the GMP requirements. With the rapid development of China's economy, GMP is a forced requirement for Chinese pharmaceutical plants and has become more and more important for those Chinese pharmaceutical companies that want to export their products to the world markets.

"GMP certificate is a rigorous process that we are delighted to have approval of reinspection successfully," began Mr. Jing'an Wang, the Chief Executive Officer of Huifeng Bio-Pharmaceutical. "The approval of GMP certificate has a significant impact on our company's future success; this further proves the superior quality standards of our products. This certification allows us to move forward to expand not only our domestic market but also our oversea markets, such as in U.S., India, European countries, Japan and South America as GMP is required by their government."

"With gaining GMP Certification, we would see great potential growth in our sales in the following quarters," Mr. Wang continued.

About Huifeng Bio-Pharmaceutical Technology, Inc.

Huifeng Bio-Pharmaceutical Technology, Inc., located in Xi'an, People's Republic of China, develops and produces plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production. It is the leading Chinese producer of rutin and related plant-derived chemicals in a class called flavonoids, with medicinal and other beneficial properties. Founded in 2002, Huifeng uses proprietary patented processes to extract rutin more efficiently than traditional extraction techniques. The Company is diversifying its product lines through internal development, acquisition and cooperation with scientific research organizations. More information can be found on the Company's web site at: http://www.hfgb.cn/

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including changes from anticipated levels of sales, future national or regional economic and competitive conditions, changes in relationships with customers, access to capital, difficulties in developing and marketing new products, marketing existing products, customer acceptance of existing and new products, and other factors disclosed in the Company's Annual Report on Form 10K for the year ended Dec. 31, 2009 and all of the Company's subsequent Quarterly Reports on Form 10Q, especially in the "Risk Factors" sections of these reports. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this press release.

For more information, please contact:



Investor Relations:

NUWA GROUP

Mr. Kevin Fickle

Tel: [phone]

Email: [e-mail]



Company Contact:

Huifeng Bio-Pharmaceutical Technology, Inc.

Ms. Bing He

Tel: [phone]

Email: [e-mail]





SOURCE Huifeng Bio-Pharmaceutical Technology, Inc.


Investor Relations: NUWA GROUP, Mr. Kevin Fickle, [phone], [e-mail]; or Company Contact: Huifeng Bio-Pharmaceutical Technology, Inc., Ms. Bing He, [phone], [e-mail]




Source: PR Newswire (September 23, 2010 - 11:37 AM EDT)

News by QuoteMedia
www.quotemedia.com